학술논문
Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
Document Type
Article
Author
Source
In Molecular & Cellular Proteomics September 2023 22(9)
Subject
Language
ISSN
1535-9476
Abstract
In Brief The in-depth proteomic platform quantifies more than 1000 proteins and classifies the DLBCL patients into four subtypes with distinct prognosis. Among signature proteins of PS-IV subtype with the worst prognosis, TIMP-1 was identified to be associated with poor prognosis and validated in two independent cohorts, which may help improve the prognostic ability of the IPI score for R-CHOP treatment.